LEO Pharma strengthens global leadership team with appointment of new Executive Vice President, Global Therapeutic & Value Strategy
Ballerup, September 23, 2020 – LEO Pharma A/S today announced that Becki Morison will join the Global Leadership Team as Executive Vice President, Global Therapeutic & Value Strategy, effective October 1.
Morison joins LEO Pharma from Eli Lilly, where she was VP, US Immunology. Prior to that, she held several leadership positions in the US, Australia as well as in the United Kingdom and the Nordics. In addition to her international experience, Morison has a proven track record in building and growing innovative pharmaceutical
franchises in different therapeutic areas including orphan diseases.
“Becki Morison’s broad knowledge in immunology, dermatology and specialty pharma will help us to strategically develop our innovative portfolio and execute global launches of best or first-in-class medicines, which is essential to reach our ambition of becoming a global leader in medical dermatology,” said Catherine Mazzacco, President and CEO of LEO Pharma.
Morison succeeds Patrice Baudry, who will take over responsibility for establishing LEO Pharma’s rare disease presence.
“Patrice Baudry’s medical background and his experience in building strong value propositions for our medicines, as he did successfully for our thrombosis business, will be vital in establishing LEO Pharma in rare dermatologic diseases,” Mazzacco continued.
+45 3140 6180
About LEO Pharma
The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma strengthens global leadership team with appointment of Jörg Möller as Executive Vice President, Global Research and Development16.12.2020 12:15:37 CET | Press release
Ballerup, December 16, 2020 – LEO Pharma A/S today announced that Jörg Möller will join its Global Leadership Team as Executive Vice President, Global Research and Development, effective January 1, 2021. Möller joins LEO Pharma from Bayer Pharma, where he has been EVP Head of R&D and Member of the Bayer Pharma Executive Committee. A medical doctor and Ph.D. by training, Jörg Möller brings a wealth of experience from his long international career during which he was responsible for a significant global organization with main hubs in Germany, the US, Switzerland, Japan and China. He led the entire value chain from target and drug discovery through clinical development, life-cycle-management and regulatory approvals and has brought a range of successful global product approvals. His experience spans multiple therapeutic areas including dermatology and immunology and a variety of technology platforms like biologics and cell & gene therapies. He has a solid track record of working with exte
LEO Pharma completes sale of portfolio of four products to Cheplapharm15.12.2020 13:20:01 CET | Press release
BALLERUP, Denmark, December 15, 2020 – Today, LEO Pharma A/S announced that the sale of a portfolio of four non-core products to Cheplapharm for approximately EUR 300 million has been complet-ed. The agreement was announced on August 31, 2020.
LEO Pharma launches #everydaypsoriasis campaign to mark World Psoriasis Day28.10.2020 08:05:00 CET | Press release
BALLERUP, Denmark, October 28, 2020 - LEO Pharma A/S today marked World Psoriasis Day by launching a series of videos featuring patients that outline the everyday challenges of living with psoriasis. The #everydaypsoriasis videos give personal perspectives on the challenges of living with psoriasis. To accompany the patient videos, LEO Pharma staff from around the world filmed a manifesto during COVID home-working restrictions, outlining their everyday commitment to supporting patients with psoriasis: WATCH OUR MANIFESTO VIDEO HERE The #everydaypsoriasis campaign video. More information can be found at www.everydaypsoriasis.com The LEO Pharma campaign is in support of the annual International Federation of Psoriasis Associations (IFPA) World Psoriasis Day. This annual awareness day is dedicated to people living with psoriasis or psoriatic arthritis and is aimed at spreading information and raising the profile of these debilitating diseases. October 2020 marks the second year of a three
LEO Pharma sells portfolio of four products to Cheplapharm31.8.2020 12:34:26 CEST | Press release
- Sale of four products for EUR 300 million - Important milestone in LEO Pharma’s ambitious 2030 strategy with increased focus on new innovative solutions for medical dermatology - Transaction expected to close December 2020
LEO Pharma strengthens global leadership team with appointment of new EVP People & Communications18.8.2020 12:02:29 CEST | Press release
Ballerup, August 18, 2020 – LEO Pharma A/S today announced that Dennis Schmidt Pedersen will join the executive leadership team as Executive Vice President Global People & Communications, effective September 1, 2020.
LEO Pharma announces U.S. Food and Drug Administration Fast Track designation for delgocitinib cream for the treatment of adults with moderate-to-severe chronic hand eczema4.8.2020 14:05:39 CEST | Press release
The purpose of the Fast Track process is to get important potential new drugs to patients earlier (1)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom